Abstract
Vitamin C has been suggested1,2 and disputed3 as an anti-cancer agent. For cells in culture, no preferential effect against any type of cancer has yet been demonstrated. Our aim here is to show that vitamin C is selectively toxic to at least one type of malignant cell—a melanoma—at concentrations that might be attained in humans. Copper ions react with ascorbate and generate free radicals in solution4. Ascorbate when combined with copper rapidly reduces the viscosity of DN A solutions and has exhibited some carcinostatic effects on transplanted sarcoma 180 tumours in mice5. We reasoned that the elevated copper concentration in melanoma6,7 could result in a more selective toxicity for ascorbate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Deucher, W. G. Strahlentherapie 67, 143–151 (1940).
Cameron, E., Pauling, L. & Libovitz, B. Cancer Res. 39, 663–681 (1979).
Creagan, E. T. et al. New Engl. J. Med. 301, 687–690 (1979).
Peloux, Y., Nofre, C., Cier, A. & Colbert, L. Annls Inst. Pasteur, Paris 102, 6–23 (1962).
Yamafuji, K., Nakamura, Y., Omura, H., Soeda, T. & Gyotoku, K. Z. Krebsforch. 76, 1–7 (1971).
Ikonopisov, R. L. in Melanoma and Skin Cancer (ed. McCarthy, W. H.) 223–230 (International Union against Cancer, Sidney, 1972).
Horcicko, J., Borovansky, J., Duchon, B. & Prochazkova, B. Sb. lék. 79, 340–343 (1977).
Salmon, S. et al. New Engl. J. Med. 298, 1322–1327 (1978).
Weininger, J., Guichard, M., Joly, A. M., Malaise, E. P. & Lachet, B. Int. J. Radiat. Biol 34, 285–290 (1978).
Lotan, R., Giotta, G., Nork, E. & Nicolson, G. L. J. natn. Cancer Inst. 60, 1035–1041 (1978).
Benade, L., Howard, T. & Burk, D. Oncology 23, 33–43 (1969).
Jungeblut, C. W. J. exp. Med. 62, 517–521 (1935).
Barron, E., Meio, R. & Klempherer, F. J. biol. Chem. 112, 625–632 (1936).
Dodin, A. C. r. hebd. Séanc. Acad. Sci., Paris 258, 2707–2710 (1964).
Lwoff, A. Annls Inst. Pasteur, Paris 84, 225–241 (1953).
Stich, H. F., Karim, J., Koropatnick, J. & Lo, L. Nature 260, 722–723 (1976).
Prasad, K. N., Sinha, P. K., Ramanujam, M. & Sakamoto, A. Proc. natn. Acad. Sci., U.S.A. 76, 829–832 (1979).
Dyer, H. M. & Ross, H. E. J. natn. Cancer Inst. 11, 313–318 (1950).
Chatterjee, G. C. in The Vitamins (eds Sebrel, L. W. & Harris, R. S.) 399–406 (Academic, New York, 1969).
Park, C. H., Bergsagel, D. E. & McCalloch, E. A. Science 174, 720–721 (1971).
Koch, C. J. & Biaglow, J. E. J. cell. Physiol. 94, 299–306 (1978).
Pawelek, J. M. & Lerner, A. B. Nature 276, 627–628 (1978).
Tomita, Y. & Seiji, M. J. Derm. 4, 245–249 (1977).
Cooper, M. & Maclean, N. Yale J. Biol. Med. 46, 705–706 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bram, S., Froussard, P., Guichard, M. et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature 284, 629–631 (1980). https://doi.org/10.1038/284629a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/284629a0
- Springer Nature Limited
This article is cited by
-
Roles of vitamins in stem cells
Cellular and Molecular Life Sciences (2020)
-
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
BMC Cancer (2019)
-
Molecular mechanisms of pharmacological doses of ascorbate on cancer cells
Wiener Medizinische Wochenschrift (2015)
-
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Cancer Chemotherapy and Pharmacology (2013)
-
Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress
BMC Complementary and Alternative Medicine (2012)